Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

February 23, 2018

Study Completion Date

February 23, 2018

Conditions
End Stage Renal Diseases
Interventions
PROCEDURE

HEMO2Life® use in organ preservation solution

The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.

Trial Locations (6)

29200

CHRU Brest, Brest

37044

CHRU de Tours, Tours

69003

Hôpital Edouard Herriot, Lyon

75013

Hôpital la Pitié Salpetrière, Paris

86021

CHU Poitiers, Poitiers

87042

CHU Limoges, Limoges

All Listed Sponsors
lead

University Hospital, Brest

OTHER

NCT02652520 - Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP) | Biotech Hunter | Biotech Hunter